GLI1 and cancer: Furthermore, the clinically approved chemotherapeutic agent arsenic trioxide (ATO) (TRISENOXTM) has been identified as potent inhibitor of GLI activity, adding another promising compound to the growing drug armamentarium against HH-driven cancers [34, 35].